Automating Genetic Testing Inpatient Admission Prior Auth

Klivira streamlines the complex and time-sensitive workflow of genetic testing inpatient admission prior authorization, ensuring rapid approvals and compliant concurrent reviews.

Managing prior authorizations for inpatient admissions involving genetic testing presents unique challenges, from emergent notifications to ongoing concurrent stay reviews. The intersection of high-cost genetic panels and critical inpatient care demands an agile, accurate, and automated solution to prevent delays and financial exposure.

The Intersection of Genetic Testing and Inpatient Prior Authorization

Genetic testing, encompassing hereditary cancer panels, prenatal diagnostics, and pharmacogenomics, often involves high-cost services and complex clinical pathways. When these tests or their downstream implications necessitate an inpatient admission, the prior authorization process becomes critical and time-sensitive. This includes initial admission notification and subsequent continued stay reviews, often managed by specialized RBMs such as eviCore or Avalon Healthcare Services.

Automating Time-Sensitive Inpatient Workflows

Klivira's platform automates the inpatient admission prior authorization workflow, triggered by real-time HL7 v2 ADT events from your EMR. For genetic testing-related admissions, this ensures immediate payer identification and submission of required admission notifications within payer-mandated windows. This is crucial for conditions identified via genetic testing that may require urgent inpatient interventions or specialized drug regimens.

Evidence-Based Appropriateness and Concurrent Review

Our system applies industry-standard criteria like MCG and InterQual, leveraging EMR data to assess the appropriateness of inpatient vs. observation status for genetic testing-related admissions. For ongoing care, Klivira facilitates daily concurrent reviews by pushing periodic FHIR-based clinical updates to payers, justifying continued stays based on evolving patient needs and clinical guidelines from bodies such as NCCN or ASCO.

Payer Connectivity and Regulatory Compliance

Klivira connects to payers through multiple channels, including direct payer portals, X12 278 transactions, and Da Vinci PAS where supported. For lines of business impacted by CMS-0057-F (e.g., MA, Medicaid managed care), our system helps ensure admission PA decisions adhere to the 72-hour standard or 24-hour expedited timeframes, minimizing compliance risks for genetic testing patients requiring inpatient care.

Optimizing Observation vs. Inpatient Determination

A specific challenge in genetic testing-related admissions is accurately determining the appropriate level of care. Klivira's logic analyzes clinical data at admission to surface recommendations for inpatient or observation status, aligning with payer criteria and preventing costly rejections due to misclassification. This precision is vital when managing high-cost genetic test outcomes and their subsequent treatment plans.

Frequently asked questions

How does Klivira handle RBMs like eviCore or Avalon for genetic testing inpatient PAs?

Klivira integrates with common RBMs, including eviCore and Avalon Healthcare Services, streamlining the submission and tracking of prior authorizations for genetic testing-related inpatient admissions. Our system ensures that specific RBM requirements and data submission protocols are met automatically, reducing manual effort and potential delays.

What EMR data points are critical for genetic testing admission PA automation?

For genetic testing admission PA, critical EMR data points include patient demographics, diagnosis codes, order details for genetic tests, test results, clinical notes justifying admission, and treatment plans. Klivira ingests this data via HL7 v2 ADT events and FHIR-based updates to inform payer submissions and concurrent reviews.

How does Klivira manage concurrent reviews for genetic testing patients during an inpatient stay?

Klivira automates daily concurrent reviews by pushing relevant clinical updates, often via FHIR, to the payer. This includes documentation of patient progress, ongoing medical necessity, and adherence to evidence-based guidelines, ensuring continuous authorization for genetic testing patients' inpatient care without manual intervention.

How does Klivira distinguish between inpatient and observation status for genetic testing-related admissions?

Klivira's platform applies embedded MCG or InterQual criteria to EMR data at the point of admission. For genetic testing-related cases, this logic helps determine whether the clinical picture meets inpatient criteria or warrants observation status, surfacing the appropriate recommendation to ensure accurate billing and authorization.

Can Klivira integrate with our EMR to pull genetic testing results for PA submissions?

Yes, Klivira integrates with your EMR via standard interfaces like HL7 v2 and FHIR. This allows our platform to ingest relevant genetic testing results and associated clinical documentation directly from the EMR, populating prior authorization requests with the necessary clinical evidence for payer review.

Related coverage

Other genetic-testing prior auth workflows

Ready to automate this workflow for this specialty?

See how Klivira automates prior authorizations for your team.

Request a demo